Sage's depression drug succeeds in mid-stage study, shares soar

Leslie Hanson
December 7, 2017

It closed at $0.05 lastly. The Price to Cash Flow for Sage Therapeutics, Inc.

"There are now significant gaps in the disease management of depression and our development goal at Sage is to change patients' expectations by transforming the treatment landscape for MDD", said Steve Kanes, M.D., Ph.D., chief medical officer of Sage Therapeutics. Visit MarketWatch.com for more information on this news. The 6 months bullish chart indicates low risk for the $6.60B company. If the $165.55 price target is reached, the company will be worth $197.97M more. About 3.06M shares traded or 259.64% up from the average. Ameritas Investment Partners Inc. lifted its holdings in shares of Sage Therapeutics by 19.6% in the second quarter. It has outperformed by 99.75% the S&P500. Sage Therapeutics, Inc. now has an average analyst recommendation of 1.70 according to analysts. (NASDAQ:SAGE) to report earnings on February, 22. Stifel Nicolaus assumed coverage on shares of Sage Therapeutics in a report on Wednesday, August 9th. Therefore 88% are positive. SAGE Therapeutics has $145.0 highest and $18 lowest target. They presently have a $112.00 target price on the biopharmaceutical company's stock, up from their previous target price of $85.67. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel.

Sage Therapeutics (NASDAQ:SAGE)'s stock had its "outperform" rating reaffirmed by analysts at BMO Capital Markets in a research note issued on Friday, November 17th. BidaskClub downgraded shares of Sage Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, July 31st.

Shares of SAGE Therapeutics (SAGE) opened at 68.95 on Friday.

The stock of Sage Therapeutics, Inc. Leerink Swann maintained the stock with "Buy" rating in Tuesday, June 20 report. As per Tuesday, September 12, the company rating was maintained by Needham. SAGE-217 was discovered by Sage, and the Company maintains worldwide rights to the compound.


The clinical-stage biopharmaceutical company's shares soared 52 percent following the test results. The company's market cap is $2.58 billion. The Company's lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus, as well as for the treatment of post-partum depression (PPD). Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.

The Sage Therapeutics Inc. announced positive results from the Phase 2 clinical trial assessing for SAGE-217, its experimental drug to treat people with moderate to severe major depressive disorder (MDD).

Investors sentiment decreased to 0.98 in Q2 2017. Its down 0.13, from 1.11 in 2017Q1. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. Alps Advisors reported 0.02% stake.

State Board Of Administration Of Florida Retirement invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Td Asset invested in 76,630 shares. Bancorporation Of Montreal Can, Ontario - Canada-based fund reported 204 shares.

Sphera Funds holds 0.07% or 5,000 shares. D E Shaw Co holds 0.01% or 64,597 shares in its portfolio. Samlyn Llc has 0.09% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 12,232 shares. Nicholas Invest Limited Partnership stated it has 0.43% of its portfolio in Sage Therapeutics, Inc.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER